- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04502056
Covid-19 Messaging to Underserved Communities - 2nd Experiment
Study Overview
Status
Conditions
Intervention / Treatment
- Behavioral: Acknowledgement Racial Injustice AMA
- Behavioral: African American Sender Acknowledgement
- Behavioral: African American Sender in Informational Videos.
- Behavioral: Racial Inequality Highlighted
- Behavioral: No Racial Inequality Highlighting
- Behavioral: White Sender in Acknowledgement
- Behavioral: White Sender in Informational Videos
- Behavioral: AMA Acknowledgement Drug Pricing
- Behavioral: Placebo videos
Detailed Description
Recent data have shown that covid19 is disproportionately infecting and killing African Americans and Latinx people in the United States. Moreover, since our last experiment, the killing of George Floyd by Minnesota police has raised awareness of structural racism in the United States.
The aim of the study is to build off results from our first experiment (NCT04371419) , and test whether messages that acknowledge racial injustice on behalf of institutions affect the retention of knowledge and movement of beliefs and behavior with respect to Covid-19. The investigators will also test the effect of concordance of providers and whether highlighting the unequal burden of the disease has additional effects on knowledge, beliefs and behavior regarding covid-19.The sample will include African American and white adult Americans and oversample those with less than a college degree.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Massachusetts
-
Cambridge, Massachusetts, United States, 02138
- JPAL North America
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- adults who self-identify as African American or white.
- an oversample of individuals with less than a college education
Exclusion Criteria:
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: AMA RI - B- B - R
Respondents will be randomized to an AMA statement acknowledging racial injustice read by an African American individual.
The messenger / doctor in the follow-up AMA videos will also be African American - the message on Covid-19 will include information on the disproportionate impact on communities of color.
|
Investigators will examine whether acknowledgements of racial inequality are helpful towards improving knowledge retention and behaviors associated with the intervention among participants.
In this arm, participants will receive a AMA statement on racial injustice.
Investigators will also vary the messenger of the acknowledgement sender.
In this arm participants receive a African American sender in acknowledgment of AMA
Investigators will vary the sender of the informational covid-19 videos.
In this arm, participants receive a African American sender in informational videos.
Investigators will include information on race-specific covid-19 cases and deaths in one variation in the messaging.
In this arm, participants receive disproportionate race-specific Covid-19 facts
|
Experimental: AMA RI - B - B - N
Respondents will be randomized to an AMA statement acknowledging racial injustice read by an African American individual.
The messenger / doctor in the follow-up AMA videos will also be African American - the message on Covid-19 will not include information on the disproportionate impact on communities of color.
|
Investigators will examine whether acknowledgements of racial inequality are helpful towards improving knowledge retention and behaviors associated with the intervention among participants.
In this arm, participants will receive a AMA statement on racial injustice.
Investigators will also vary the messenger of the acknowledgement sender.
In this arm participants receive a African American sender in acknowledgment of AMA
Investigators will vary the sender of the informational covid-19 videos.
In this arm, participants receive a African American sender in informational videos.
In this arm, the disproportionate burden of Covid-19 on communities of color will not be highlighted
|
Experimental: AMA RI - W - W - R
Respondents will be randomized to an AMA statement acknowledging racial injustice read by a white individual.
The messenger / doctor in the follow-up AMA videos will be white - the message on Covid-19 will include information on the disproportionate impact on communities of color.
|
Investigators will examine whether acknowledgements of racial inequality are helpful towards improving knowledge retention and behaviors associated with the intervention among participants.
In this arm, participants will receive a AMA statement on racial injustice.
Investigators will include information on race-specific covid-19 cases and deaths in one variation in the messaging.
In this arm, participants receive disproportionate race-specific Covid-19 facts
Investigators will also vary the messenger of the acknowledgement sender.
In this arm, participants receive a white sender in the acknowledgement
Investigators will vary the messenger of the informational covid-19 videos.
In this arm, participants receive white sender in the informational video
|
Experimental: AMA RI - W - W - N
Respondents will be randomized to an AMA statement acknowledging racial injustice read by a white individual.
The messenger / doctor in the follow-up AMA videos will be white - the message on Covid-19 will not include information on the disproportionate impact on communities of color.
|
Investigators will examine whether acknowledgements of racial inequality are helpful towards improving knowledge retention and behaviors associated with the intervention among participants.
In this arm, participants will receive a AMA statement on racial injustice.
In this arm, the disproportionate burden of Covid-19 on communities of color will not be highlighted
Investigators will also vary the messenger of the acknowledgement sender.
In this arm, participants receive a white sender in the acknowledgement
Investigators will vary the messenger of the informational covid-19 videos.
In this arm, participants receive white sender in the informational video
|
Experimental: AMA DP - B- B - R
Respondents will be randomized to an AMA statement acknowledging drug pricing read by an African American individual.
The messenger / doctor in the follow-up AMA videos will also be African American - the message on Covid-19 will include information on the disproportionate impact on communities of color .
|
Investigators will also vary the messenger of the acknowledgement sender.
In this arm participants receive a African American sender in acknowledgment of AMA
Investigators will vary the sender of the informational covid-19 videos.
In this arm, participants receive a African American sender in informational videos.
Investigators will include information on race-specific covid-19 cases and deaths in one variation in the messaging.
In this arm, participants receive disproportionate race-specific Covid-19 facts
Investigators will examine whether acknowledgements of racial inequality are helpful towards improving knowledge retention and behaviors associated with the intervention among participants.
In this arm, participants receive AMA information on drug pricing
|
Experimental: AMA DP - B- B - N
Respondents will be randomized to an AMA statement acknowledging drug pricing read by an African American individual.
The messenger / doctor in the follow-up AMA videos will also be African American - the message on Covid-19 will not include information on the disproportionate impact on communities of color.
|
Investigators will also vary the messenger of the acknowledgement sender.
In this arm participants receive a African American sender in acknowledgment of AMA
Investigators will vary the sender of the informational covid-19 videos.
In this arm, participants receive a African American sender in informational videos.
In this arm, the disproportionate burden of Covid-19 on communities of color will not be highlighted
Investigators will examine whether acknowledgements of racial inequality are helpful towards improving knowledge retention and behaviors associated with the intervention among participants.
In this arm, participants receive AMA information on drug pricing
|
Experimental: AMA DP - W- W - R
Respondents will be randomized to an AMA statement acknowledging drug pricing read by a white individual.
The messenger / doctor in the follow-up AMA videos will be white - the message on Covid-19 will include information on the disproportionate impact on communities of color.
|
Investigators will include information on race-specific covid-19 cases and deaths in one variation in the messaging.
In this arm, participants receive disproportionate race-specific Covid-19 facts
Investigators will also vary the messenger of the acknowledgement sender.
In this arm, participants receive a white sender in the acknowledgement
Investigators will vary the messenger of the informational covid-19 videos.
In this arm, participants receive white sender in the informational video
Investigators will examine whether acknowledgements of racial inequality are helpful towards improving knowledge retention and behaviors associated with the intervention among participants.
In this arm, participants receive AMA information on drug pricing
|
Experimental: AMA DP - W- W - N
Respondents will be randomized to an AMA statement acknowledging drug pricing read by a white individual.
The messenger / doctor in the follow-up AMA videos will be white - the message on Covid-19 will not include information on the disproportionate impact on communities of color.
|
In this arm, the disproportionate burden of Covid-19 on communities of color will not be highlighted
Investigators will also vary the messenger of the acknowledgement sender.
In this arm, participants receive a white sender in the acknowledgement
Investigators will vary the messenger of the informational covid-19 videos.
In this arm, participants receive white sender in the informational video
Investigators will examine whether acknowledgements of racial inequality are helpful towards improving knowledge retention and behaviors associated with the intervention among participants.
In this arm, participants receive AMA information on drug pricing
|
Placebo Comparator: Control: AMA RI - B - B
Respondents will be randomized to an AMA statement acknowledging racial injustice read by an African American individual. The messenger / doctor in the follow-up AMA videos will also be African American - No message on Covid-19 will be shown. Acknowledgement Racial Injustice AMA: Investigators will examine whether acknowledgements of racial inequality are helpful towards improving knowledge retention and behaviors associated with the intervention among participants. In this arm, participants will receive a AMA statement on racial injustice. African American Sender Acknowledgement: Investigators will also vary the messenger of the acknowledgement sender. In this arm participants receive a African American sender in acknowledgment of AMA |
Investigators will examine whether acknowledgements of racial inequality are helpful towards improving knowledge retention and behaviors associated with the intervention among participants.
In this arm, participants will receive a AMA statement on racial injustice.
Investigators will also vary the messenger of the acknowledgement sender.
In this arm participants receive a African American sender in acknowledgment of AMA
Investigators will vary the sender of the informational covid-19 videos.
In this arm, participants receive a African American sender in informational videos.
Videos not related to covid-19 will be shown
|
Placebo Comparator: Control: AMA RI - W - W
Respondents will be randomized to an AMA statement acknowledging racial injustice read by a white individual. The messenger / doctor in the follow-up AMA videos will also be white - No message on Covid-19 will be shown. Acknowledgement Racial Injustice AMA: Investigators will examine whether acknowledgements of racial inequality are helpful towards improving knowledge retention and behaviors associated with the intervention among participants. In this arm, participants will receive a AMA statement on racial injustice. White Sender Acknowledgement: Investigators will also vary the messenger of the acknowledgement sender. In this arm participants receive a white sender in acknowledgment of AMA |
Investigators will examine whether acknowledgements of racial inequality are helpful towards improving knowledge retention and behaviors associated with the intervention among participants.
In this arm, participants will receive a AMA statement on racial injustice.
Investigators will also vary the messenger of the acknowledgement sender.
In this arm, participants receive a white sender in the acknowledgement
Investigators will vary the messenger of the informational covid-19 videos.
In this arm, participants receive white sender in the informational video
Videos not related to covid-19 will be shown
|
Placebo Comparator: Control: AMA DP - B - B
Respondents will be randomized to an AMA statement acknowledging drug pricing read by an African American individual. The messenger / doctor in the follow-up AMA videos will also be African American - No message on Covid-19 will be shown. African American Sender Acknowledgement: Investigators will also vary the messenger of the acknowledgement sender. In this arm participants receive a African American sender in acknowledgment of AMA AMA Acknowledgement Drug Pricing: Investigators will examine whether acknowledgements of racial inequality are helpful towards improving knowledge retention and behaviors associated with the intervention among participants. In this arm, participants receive AMA information on drug pricing |
Investigators will also vary the messenger of the acknowledgement sender.
In this arm participants receive a African American sender in acknowledgment of AMA
Investigators will vary the sender of the informational covid-19 videos.
In this arm, participants receive a African American sender in informational videos.
Investigators will examine whether acknowledgements of racial inequality are helpful towards improving knowledge retention and behaviors associated with the intervention among participants.
In this arm, participants receive AMA information on drug pricing
Videos not related to covid-19 will be shown
|
Placebo Comparator: Control: AMA DP - W - W
Respondents will be randomized to an AMA statement acknowledging drug pricing read by a white individual. The messenger / doctor in the follow-up AMA videos will also be white - No message on Covid-19 will be shown. White Sender Acknowledgement: Investigators will also vary the messenger of the acknowledgement sender. In this arm participants receive a white sender in acknowledgment of AMA AMA Acknowledgement Drug Pricing: Investigators will examine whether acknowledgements of racial inequality are helpful towards improving knowledge retention and behaviors associated with the intervention among participants. In this arm, participants receive AMA information on drug pricing |
Investigators will also vary the messenger of the acknowledgement sender.
In this arm, participants receive a white sender in the acknowledgement
Investigators will vary the messenger of the informational covid-19 videos.
In this arm, participants receive white sender in the informational video
Investigators will examine whether acknowledgements of racial inequality are helpful towards improving knowledge retention and behaviors associated with the intervention among participants.
In this arm, participants receive AMA information on drug pricing
Videos not related to covid-19 will be shown
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence Rate for Knowledge Gaps: Control vs. Any Intervention
Time Frame: The outcome was measured immediately following the intervention in the baseline survey.
|
Participants were asked to identify ways to prevent COVID-19 spread and identify four common symptoms.
The incidence rate for knowledge gaps is the count of knowledge gaps divided by the maximum possible count: 10.
|
The outcome was measured immediately following the intervention in the baseline survey.
|
Incidence Rate for Knowledge Gaps: Control vs. Any Intervention - Follow up
Time Frame: The outcome was measured at a follow-up within 2 weeks following the intervention
|
Participants were asked to identify ways to prevent COVID-19 spread and identify four common symptoms.
Incidence rate for knowledge gaps is the count of knowledge gaps divided by the maximum possible count: 10.
|
The outcome was measured at a follow-up within 2 weeks following the intervention
|
Incidence Rate for Information-seeking Behavior: Control vs. Any Intervention
Time Frame: The outcome was measured immediately following the intervention in the baseline survey.
|
Participants were offered the option of requesting additional information on COVID-19 related resources by clicking on up to five links that included more content.
We measured "information seeking behavior" as the number of links for which participants expressed interest, a count variable between 0 (lowest information seeking behavior) and 5 (greatest information seeking behavior).
Incidence rate for interest in links is the count of links demanded divided by the maximum possible count: 5.
|
The outcome was measured immediately following the intervention in the baseline survey.
|
Incidence Rate - Safety Gap Score: Control vs. Any Intervention
Time Frame: The outcome was measured at a follow-up within 2 weeks following the intervention.
|
Participants were asked about how often they engaged in four behaviors of interest: if they wore a mask indoors/outdoors; if they washed their hands; if they followed social distancing guidelines.
The safety gap index takes values of 0 (if a participant reported that they always practiced the four behaviors of interest) up to 4 (none).
Incidence rate for safety gaps is the count of safety gaps divided by the maximum possible count: 4.
|
The outcome was measured at a follow-up within 2 weeks following the intervention.
|
Willingness to Pay (WTP) for Masks: Control vs. Any Intervention
Time Frame: The outcome was measured immediately following the intervention in the baseline survey.
|
WTP: the participants will be asked to choose between two masks vs an unrestricted gift card.
They will be asked what amount of gift card would make them just as happy to receive two mask versus the gift card.
|
The outcome was measured immediately following the intervention in the baseline survey.
|
Incidence Rate Ratio (IRR) - Knowledge Gap
Time Frame: The outcome was measured immediately following the intervention in the baseline survey.
|
Participants were asked to identify ways to prevent COVID-19 spread and identify four common symptoms.
The incidence rate for knowledge gaps is the count of knowledge gaps divided by the maximum possible count: 10.
The incidence rate ratio compares the incidence rate of participants in Arm A vs. Arm B within the intervention group (i.e.
those who received covid-19-related videos), within in the control group (i.e.
those who saw placebo videos), or across the intervention and control group.
Arms A and B are described in each Arm/Group Title.
The overall number of participants analyzed is all equal across 6 arms/groups because the outcome measure data presented below came from a single negative binomial regression.
|
The outcome was measured immediately following the intervention in the baseline survey.
|
Incidence Rate Ratio (IRR) - Knowledge Gap - Follow up
Time Frame: The outcome was measured at a follow-up within 2 weeks following the intervention
|
Participants were asked to identify ways to prevent COVID-19 spread and identify four common symptoms.
The incidence rate for knowledge gaps is the count of knowledge gaps divided by the maximum possible count: 10.
The incidence rate ratio compares the incidence rate of participants in Arm A vs. Arm B within the intervention group (i.e.
those who received covid-19-related videos), within in the control group (i.e.
those who saw placebo videos), or across the intervention and control group.
Arms A and B are described in each Arm/Group Title.
The overall number of participants analyzed is all equal across 6 arms/groups because the outcome measure data presented below came from a single negative binomial regression.
|
The outcome was measured at a follow-up within 2 weeks following the intervention
|
Incidence Rate Ratio (IRR) - Information-seeking Behavior
Time Frame: The outcome was measured immediately following the intervention in the baseline survey.
|
Participants were offered the option of requesting additional information on COVID-19 related resources by clicking on up to 5 links that included more content.
We measured "information seeking behavior" as the number of links for which participants expressed interest, a count variable between 0 (lowest information seeking behavior) and 5 (greatest information seeking behavior).
Incidence rate for interest in links is the count of links demanded divided by the maximum possible count: 5.
The incidence rate ratio compares the incidence rate of participants in Arm A vs. Arm B within the intervention group (i.e.
those who received covid-19-related videos), within in the control group (i.e.
those who saw placebo videos), or across the intervention and control group.
Arms A and B are described in each Arm/Group Title.
The overall number of participants analyzed is all equal across 6 arms/groups because the outcome measure data presented below came from a single negative binomial regression.
|
The outcome was measured immediately following the intervention in the baseline survey.
|
Incidence Rate Ratio (IRR) - Safety Gap Score
Time Frame: The outcome was measured at a follow-up within 2 weeks following the intervention.
|
Participants were asked about how often they engaged in four behaviors of interest: if they wore a mask indoors/outdoors; if they washed their hands; if they followed social distancing guidelines.
The safety gap index takes values of 0 (if a participant reported that they always practiced the four behaviors of interest) up to 4 (none).
Incidence rate for safety gaps is the count of safety gaps divided by the maximum possible count: 4. The incidence rate ratio compares the incidence rate of participants in Arm A vs. Arm B within the intervention group (i.e.
those who received covid-19-related videos), within in the control group (i.e.
those who saw placebo videos), or across the intervention and control group.
Arms A and B are described in each Arm/Group Title.
The overall number of participants analyzed is all equal across 6 arms/groups because the outcome measure data presented below came from a single negative binomial regression.
|
The outcome was measured at a follow-up within 2 weeks following the intervention.
|
OLS Regression Coefficients - Willingness to Pay (WTP) for Masks
Time Frame: The outcome was measured immediately following the intervention in the baseline survey.
|
WTP: the participants will be asked to choose between two masks vs an unrestricted gift card.
They will be asked what amount of gift card would make them just as happy to receive two mask versus the gift card.
The regression coefficients compares the incidence rate of participants in Arm A vs. Arm B within the intervention group (i.e.
those who received covid-19-related videos), within in the control group (i.e.
those who saw placebo videos), or across the intervention and control group.
Arms A and B are described in each Arm/Group Title.
The overall number of participants analyzed is all equal across 6 arms/groups because the outcome measure data presented below came from a single ordinary least squares (OLS) regression for WTP masks).
|
The outcome was measured immediately following the intervention in the baseline survey.
|
Collaborators and Investigators
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2029880
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Covid19
-
Anavasi DiagnosticsNot yet recruiting
-
Ain Shams UniversityRecruiting
-
Israel Institute for Biological Research (IIBR)Completed
-
Colgate PalmoliveCompleted
-
Christian von BuchwaldCompleted
-
Luye Pharma Group Ltd.Shandong Boan Biotechnology Co., LtdActive, not recruiting
-
University of ZurichLabor Speiz; Swiss Armed Forces; Universitätsspital ZürichEnrolling by invitation
-
Alexandria UniversityCompleted